American Elm Allergy Shots: Spring Pollen After Dutch Elm Disease
American elm (Ulmus americana) once defined Eastern US streetscapes before Dutch elm disease devastated populations; today it pollinates from surviving riparian stands and disease-resistant cultivars each February–April. No IUIS-named allergen exists, no SCIT RCT has been published, yet 24.6% sensitization in US patients confirms clinical relevance — and patients recalling childhood street trees often discover their current sensitization is actually Chinese or cedar elm.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
American Elmis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
American Elm Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to american elm — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of american elm allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of american elm immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of american elm extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for american elm allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing american elm extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription american elm immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat american elm allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is American Elm?
The biology, taxonomy, and clinical fingerprint of American Elm — the foundation of how SCIT targets it.
American elm releases pollen from bare branches in February–April before leaves emerge, from surviving disease-resistant cultivars and riparian stands.
- Scientific name
- Ulmus americana
- Family
- UlmaceaeElm family
- Type
- Tree pollen — wind-pollinated deciduous catkins
- Native to
- Eastern and central North America
- Allergen proteins
- No formally named IUIS allergen for Ulmus americana as of May 2026
- Particle size
- 23–38 µm equatorial diameter, oblate, stephanoporate (5–6 pores)
- Avoidance difficulty
- Very difficult
How American Elm Allergy Presents
Symptoms by body system — useful for distinguishing American Elm sensitivity from overlapping allergies and infections.
Respiratory
- Sneezing attacks during the February–April spring elm pollen window
- Nasal congestion and rhinorrhea coinciding with pre-leaf catkin release
- Worsening allergic asthma during early spring elm season
- Post-nasal drip and throat clearing on high pollen-count days
- Persistent cough triggered by outdoor early-spring exposure
Ocular
- Watery, itchy eyes during February–April elm pollen release
- Conjunctival injection and periorbital puffiness on high-count days
- Contact lens intolerance during spring elm season
- Photosensitivity associated with severe conjunctival irritation
Dermal
- Flaring of atopic dermatitis during peak spring elm pollen season
- Contact urticaria from handling cut elm branches (uncommon)
- Facial flushing in highly sensitized patients on extreme pollen days
Systemic
- Fatigue and cognitive fog during peak early-spring elm pollen load
- Sleep disruption from nasal congestion overlapping the February–April window
- Reduced exercise tolerance in patients with elm-triggered asthma
- Generalized malaise in patients with concurrent early-spring sensitizations
Patients in their 60s often tell me their childhood streets were lined with American elms. Most of those trees are gone — and the IgE they're reacting to today is usually from Chinese elm naturalized in the same neighborhoods, not the vanished species they remember.
When & Where American Elm Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: mid-February through early April across the Eastern US — pre-leaf catkin release from bare branches· ~6–8 weeks of pollen season; now starting ~20 days earlier than in 1990 (Anderegg et al., PNAS 2021)
US Exposure Map
11 high-intensity statesExposure intensity by state (text version)
- ME:
- Moderate
- VT:
- Moderate
- NH:
- Moderate
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Moderate
- WI:
- Moderate
- MI:
- Moderate
- NY:
- High
- MA:
- Moderate
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Moderate
- IL:
- High
- IN:
- High
- OH:
- High
- PA:
- High
- NJ:
- High
- CT:
- Moderate
- RI:
- Moderate
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Moderate
- KY:
- High
- WV:
- High
- VA:
- High
- MD:
- High
- DE:
- Moderate
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Moderate
- TN:
- High
- NC:
- Moderate
- SC:
- Moderate
- OK:
- Low
- LA:
- Moderate
- MS:
- Moderate
- AL:
- Moderate
- GA:
- Moderate
- TX:
- Low
- FL:
- Low
- AK:
- Low
- HI:
- Low
What American Elm Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
American elm cross-reactivity is largely confined to the Ulmaceae family; animal antisera and IgE studies show little cross-reactivity between elms and Fagales or Oleaceae tree families (Lewis & Vinay).
Strong intra-Ulmaceae cross-reactivity; naturalized urban replacement for U. americana
Is SCIT Right for Your American Elm Allergy?
Answer five questions to assess whether American elm allergy shots fit your spring rhinitis profile.
How severe are your February–April spring elm pollen symptoms?
The American Elm SCIT Protocol
American elm SCIT uses a non-standardized aqueous or glycerinated extract with the build-up schedule individually calibrated, because no FDA-standardized Ulmus americana extract exists.
Starting from the most dilute vial, your allergist increases the elm extract dose at each visit over 6–8 months. The 30-minute post-injection observation period is mandatory to detect any systemic reaction. Build-up is ideally timed to complete before the February elm season in your region.
At the maintenance dose your immune system continues to modulate its response to elm pollen proteins. Patients observe a 30-minute post-injection wait at each maintenance visit. Annual symptom diaries help track progress across successive elm pollen seasons.
After a successful course, many patients sustain meaningful symptom reduction for years after stopping SCIT. The decision to discontinue is made collaboratively after reviewing symptom scores across at least two successive elm seasons.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for American Elm SCIT
No randomized controlled trial has been published specifically for American elm SCIT. Clinical support comes from observational data linking Ulmus pollen to respiratory outcomes and the broader non-standardized tree SCIT evidence base.
- Ulmus pollen–asthma hospitalization association55%Dales et al., Int Arch Allergy Immunol 2008;146:241–247 — multi-city Canadian study
- Elm sensitization prevalence in US allergic patients25%Hoffman, cited in Ann Allergy Asthma Immunol 2014; 371-patient US series
- Estimated symptomatic benefit from non-standardized tree SCIT (extrapolated)48%Cox L et al., J Allergy Clin Immunol 2011;127:S1–S55 — Practice Parameter Third Update
American elm SCIT has no dedicated efficacy trial. Clinical prescribing follows the AAAAI/ACAAI Practice Parameter framework (Cox 2011; Greenhawt 2023), which supports immunotherapy for confirmed sensitization with inadequate pharmacotherapy response, extrapolating from better-studied tree pollen SCIT. Species-specific testing before prescribing maximizes the likelihood that the extract targets the actual sensitizer.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
American Elm SCIT Side Effects
American elm SCIT side effects are consistent with non-standardized inhalant tree extract immunotherapy; local reactions are most common and serious systemic events are rare with proper clinic protocols.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site erythema and swelling Most common; typically resolves within 4–8 hours of injection | Rate 25–50% | Mild |
Injection-site pruritus Localized itching at injection site; cool compress relieves most cases | Rate 20–35% | Mild |
Large local reaction Swelling >5 cm; may require dose adjustment at next visit | Rate 5–10% | Moderate |
Delayed local soreness Induration appearing 4–8 hours post-injection; no dose change usually needed | Rate 5–8% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis or conjunctivitis flare Transient nasal or eye symptom exacerbation; typically resolves within 30–60 minutes | Rate 0.5–1% | Mild |
Urticaria Hives beyond the injection site; requires evaluation and possible dose reduction | Rate 0.1–0.3% | Moderate |
Mild bronchospasm Managed in-clinic with bronchodilator; underlying asthma is a risk factor | Rate 0.1–0.2% | Moderate |
Anaphylaxis Extremely rare; a 30-minute self-observation, a prescribed epinephrine auto-injector confirmed on hand, and live Zoom supervision of the first injection from each new vial or concentration is designed to detect and treat it immediately. | Rate <0.01% | Severe |
SCIT has traditionally been given in a clinic equipped for emergency treatment; for eligible patients, Curex makes safe at-home self-administration possible with a personalized serum sterile-compounded to USP <797>, a prescribed epinephrine auto-injector confirmed on hand, and the first injection from each new vial or concentration supervised live in the Virtual Shot Room. A 30-minute observation follows each dose and remains a core safety step.
SCIT vs Alternatives for American Elm
American elm allergy management options span daily medications, avoidance, sublingual immunotherapy, and SCIT — now available as a weekly at-home shot with Curex; the right choice depends on symptom severity, season length, and patient preferences.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Moderate (no RCT) | Comparable (extrapolated) | Partial only | Good short-term control |
| 5-yr cost | $3,500–$9,000 | Varies by provider; offered as a general modality, not by Curex | Low | $500–$2,000/yr |
| Duration | 3–5 years | 3–5 years | Ongoing | Lifelong |
| Convenience | Weekly at-home build-up easing to ongoing maintenance with Curex | Daily drops at home | Very difficult — outdoor | Daily pill/spray |
| Safety | Very safe; sterile-compounded serum plus live Zoom supervision of every dose change | Very safe | Excellent | Generally safe |
| Lasting effect | Yes, years post-tx | Yes, years post-tx | No | No — returns off meds |
SCITBest
SLIT
Avoidance
Medications
SCIT offers the most durable long-term benefit for American elm-sensitized patients with multi-season symptoms — and with Curex, eligible patients self-administer that shot at home with pricing confirmed in a current program quote instead of attending weekly clinic injections, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room and a prescribed epinephrine auto-injector confirmed on hand.
What American Elm SCIT Actually Costs
Major US insurers generally cover American elm SCIT under standard allergy benefits when prescribed by a board-certified allergist with documented positive sensitization; prior authorization is often required, and out-of-pocket expenses depend on plan deductible and co-insurance. Curex at-home IgE testing identifies specific american elm sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your american elm allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
American Elm SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Yes — American elm remains clinically relevant despite the loss of more than 75% of mature urban specimens to Dutch elm disease since the 1930s (Hubbes 1999, Forestry Chronicle). Surviving trees in riparian corridors, urban parks, and remnant woodlands still produce pollen each February–April. More importantly, disease-resistant cultivars such as 'Princeton' and 'Valley Forge,' released by the US National Arboretum in the 1990s, are increasingly planted in municipalities seeking to restore elm canopy (Townsend et al., Arboriculture & Urban Forestry). Each newly planted tree adds to the regional pollen load. Additionally, many patients sensitized to 'American elm' on older IgE panels may actually be reacting primarily to Chinese elm — the Asian ornamental planted as a Dutch-elm-disease-resistant replacement, which sheds pollen in fall rather than spring.
American elm pollinates February–April in most of the Eastern US, overlapping with alder, red maple, and early box-elder. The key clues are symptom timing (pre-leaf catkin release, before trees green up) and geographic location — American elm exposure is highest near urban parks, riparian corridors, and residential streets in the Northeast, Mid-Atlantic, and Midwest. Definitive confirmation requires allergen-specific IgE blood testing or skin-prick testing to individual elm species. A board-certified allergist can distinguish American elm from Chinese elm (fall-shedding) and from the Fagales cluster (alder, birch, oak), each of which has a distinct seasonal window and molecular profile.
American elm SCIT follows the standard non-standardized tree extract protocol: a build-up phase of approximately 6–8 months with weekly injections, followed by a maintenance phase of maintenance injections for 3–5 years. Total treatment duration is therefore 3.5–5.5 years from first injection to the end of the recommended course. Most patients notice symptom improvement after the first full elm season on maintenance — typically 12–18 months into treatment. Because no American elm-specific RCT has been published, the timeline evidence is extrapolated from the broader non-standardized tree SCIT literature and the AAAAI/ACAAI Practice Parameter (Cox 2011).
Some patients experience a temporary increase in allergy symptoms — particularly rhinitis and eye irritation — during the early build-up phase, especially around the time elm pollen is airborne. This is a known pattern with tree SCIT and is managed by timing build-up to avoid the peak season start if possible, and by pre-medicating with antihistamines before injections during symptomatic periods. Systemic reactions (beyond local injection-site swelling) are uncommon at 0.1–0.3% per injection when dosing follows the conservative build-up schedule. The 30-minute post-injection observation period detects the rare systemic reaction before the patient leaves the clinic.
Elm pollen has been associated with increased asthma hospitalization rates in Canadian cities (Dales et al., Int Arch Allergy Immunol 2008), and allergen immunotherapy is generally supported for allergic asthma in patients who are also sensitized to the relevant allergen. The AAAAI/ACAAI Practice Parameter supports SCIT for mild-to-moderate allergic asthma when the sensitizing allergen is confirmed and the asthma is adequately controlled at baseline. For elm-sensitized patients with seasonal asthma exacerbations, immunotherapy may reduce both nasal and bronchial symptom burden — though no elm-specific asthma RCT has been published. On safety, a large safety study of self-administered immunotherapy found that across 23,614 patients giving 2,021,600 injections the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots. Asthma status must be assessed by spirometry or peak flow before each injection.
The critical clinical difference is pollination season: American elm sheds pollen February–April from bare branches in early spring, while Chinese elm (Ulmus parvifolia) sheds pollen August–November — a fall season that closely mimics ragweed timing. Both species belong to Ulmaceae and share strong intra-family cross-reactivity, but a patient sensitized primarily to Chinese elm will experience fall rather than spring symptoms, and an SCIT extract weighted toward American elm may under-dose the actual fall offender. Species-specific IgE testing to both U. americana and U. parvifolia is the appropriate workup before prescribing elm extract in regions where Chinese elm has naturalized — including most Gulf Coast, Pacific Coast, and lower Mississippi Valley cities.
American elm exposure is lower than it was before Dutch elm disease but is not negligible. The National Arboretum's disease-resistant cultivars are being planted in municipalities across the Eastern US, and surviving riparian stands in floodplains still release substantial pollen each spring. Moreover, many patients labeled as American elm-sensitized on older or less granular panels are also reacting to Chinese elm — which is increasingly common as a naturalized urban ornamental. If species-specific IgE testing confirms genuine American elm sensitization with a compatible spring symptom history, SCIT is a reasonable consideration when pharmacotherapy is inadequate. The decision should weigh symptom severity against the 3–5 year treatment commitment.
Yes — American elm SCIT is appropriate for pediatric patients with confirmed sensitization and inadequate symptom control on antihistamines and nasal steroids. The AAAAI/ACAAI Practice Parameters support allergen immunotherapy in children as young as 5 years of age in most practices. The build-up schedule and starting dose are adjusted for body weight and skin-test reactivity. The mandatory 30-minute observation period is equally important in children, and parents should be instructed to recognize early signs of a systemic reaction. A board-certified pediatric allergist can assess whether the child's spring symptom burden and American elm sensitization pattern support proceeding with immunotherapy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.